Researchers from Chulalongkorn University have developed a new weapon against glioblastoma, a notoriously difficult-to-treat brain cancer, in the form of a brand-new antibody. This antibody is a key component of a cutting-edge immunotherapy treatment that utilizes CAR T cells, which are immune cells engineered to specifically target and destroy cancer cells.
What sets this antibody apart is its exceptional ability to bind to a specific protein found on glioblastoma cells, making the CAR T cells incredibly effective at eliminating the cancer. In studies with mice, this new treatment has shown remarkable results, not only eradicating existing tumors but also preventing new ones from forming.
This discovery holds immense promise for patients diagnosed with glioblastoma, offering a potential breakthrough in the fight against this aggressive disease.
Funding
This research is funded by the Thailand Science Research and Innovation Fund (TSRI) (CU_FRB640001_01_33_4), The Program Management Unit for Human Resource & Institutional Development, Research and Innovation (PMU-B) (B16F640221), The Development and Promotion of Science and Technology Talents (DPST) Project, and the Second Century Fund (C2F), Chulalongkorn University. The academic endeavors of TTCI receive support from the National Research Council of Thailand (N34E670096).
Original Paper
Title of original paper: Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study
Journal: Journal for Immuno Therapy of Cancer
DOI: 10.1136/jitc-2024-010083